Propel testing excellence with Mayo Clinic quality
Mayo Clinic Laboratories is a one-stop laboratory solution, offering commercial laboratories a vast testing menu, unparalleled customer service, and optimized processes. We work collaboratively with partners to assess their needs, providing the testing they need to expand into new areas and meet their business goals.
As the reference lab for Mayo Clinic, we’ve developed robust logistics and testing protocols applied uniformly for all specimens received, no matter their geographic origin. Whether you send us one test order or thousands, each sample receives the same treatment and level of care, ensuring superior results that help our partners better serve their clients.
“Our clients want personal experiences. They want someone to answer the phone. They want someone to provide answers when they're looking for results of a sample sent a couple days ago. and we deliver those answers.”
Angie Reese-Davis, director of operations, logistics, and specimen services, Mayo Clinic Laboratories
Our difference
News and updates
The latest
In this episode of the “Leveraging the Laboratory” podcast, Jane Hermansen, outreach manager at Mayo Clinic Laboratories, welcomes Chelsea Conn, Mayo Clinic Laboratories’ director of regulatory affairs. Together, they break down the latest regulatory changes and share actionable strategies to help outreach programs stay informed and prepared.
Andrew McKeon, M.B., B.Ch., M.D., explains how Mayo Clinic Laboratories' pediatric autoimmune/CNS testing can better guide the treatment of autoimmune neurological diseases in children. The tailored evaluation covers only biomarkers relevant to pediatric presentations of the diseases.
This week's research roundup features: How do I warm HPC(A) products to maximize cell viability in the setting of cold agglutinin disease?
Matthew Binnicker, Ph.D., director of the Clinical Virology Laboratory at Mayo Clinic, was featured in an NBC News article about how hospitals are expecting a busy winter with an increased spread of COVID-19, influenza, and other respiratory illnesses.
Topic highlights include: FDA clears updated COVID boosters for kids as young as 5, Mayo Clinic to support Hurricane Ian disaster relief, Early jump in RSV hospitalizations concerns Minnesota experts
On this week’s episode of the "Answers From the Lab" podcast, Bobbi Pritt, M.D., is joined by Matthew Binnicker, Ph.D., director of the Clinical Virology Laboratory at Mayo Clinic. Dr. Pritt and Dr. Binnicker discuss why it could be a rough influenza season, testing options for patients with respiratory infections, and how to protect yourself from illness.
In a groundbreaking study, Mayo Clinic investigators have developed a multiomic molecular method to predict clinical COVID-19 (SARS-CoV-2) outcomes better than traditional cytokines. Using a machine-learning-based prediction model, the team identified 102 biomarkers, which include several novel cytokines and other proteins, lipids, and metabolites. The discovery may help clinicians reliably predict a more severe course of COVID-19 before the patient gets sick enough to be hospitalized. Until now, there have been no biomarkers that can reliably predict which patients are more likely to have severe illness.
Loralie Langman, Ph.D., explains the difference between chain of custody and clinical toxicology testing. Chain of custody is a process used for toxicology testing when the results might have legal implications for the individual tested. Clinical toxicology testing is used for routine medical care. Mayo Clinic Laboratories offers a full range of clinical and forensic toxicology testing.
This week's research roundup features: Transcriptomic analysis of cirrhosis-like hepatocellular carcinoma reveals distinct molecular characteristics and pathologic staging implications
Topic highlights include: New Mayo Clinic scanner is first of its kind in North America, Mayo Clinic Health System allergist shares advice for finding relief this allergy season, Vaccine appears to protect against monkeypox, CDC says
New research led by the Lunenfeld-Tannenbaum Research Institute, Mount Sinai Hospital, Toronto; Mayo Clinic Comprehensive Cancer Center; and Mayo Clinic Center for Individualized Medicine has identified the biologic mechanism of a germline alteration that may be critical for developing new therapies to treat and prevent a type of brain tumor.
In this episode of “Lab Medicine Rounds,” Justin Kreuter, M.D., sits down with Matt Binnicker, Ph.D., director of Clinical Virology and vice chair of practice in the Department of Laboratory Medicine and Pathology at Mayo Clinic, to discuss the laboratory medicine perspective of Monkeypox.
In September 2022, Mayo Clinic Laboratories announced ten new tests along with numerous reference value changes, obsolete tests, and algorithm changes.